BPC-157

Researched for its potential role in tissue repair and gut lining support. Often comes up when joint stiffness, achiness, or slow-healing soft tissue issues show up alongside hormonal shifts.

Cycle: Often dosed daily for 4–6 weeks, then reassessed before continuing.

KPV

A smaller peptide studied for anti-inflammatory effects, frequently discussed alongside BPC-157 for gut and systemic inflammation.

Cycle: Research and community reports describe 4–8 week cycles, typically dosed daily.

TB-500

Studied for supporting flexibility and recovery in connective tissue — often mentioned by women managing achy joints or slower recovery after activity.

Cycle: Often a loading phase of more frequent dosing for the first 4–6 weeks, tapering to once-weekly maintenance.

ARA-290

A peptide derived from erythropoietin, researched for nerve protection and anti-inflammatory effects — most often discussed for nerve-related pain and tissue repair, separate from its parent molecule's role in red blood cell production.

Cycle: Cycling data here is thin — most of what's known comes from structured clinical trial protocols rather than self-directed community use.

Kisspeptin-10

Researched for its role in triggering the hypothalamic signal that drives the body's natural hormone cascade — directly upstream of LH, FSH, estrogen, and testosterone production. Of particular interest during perimenopause, when that signaling naturally shifts.

Cycle: Because continuous stimulation can desensitize this pathway instead of supporting it, research and community discussions tend to favor intermittent dosing — a few times a week rather than daily. This is one where the pattern matters as much as the dose.

GHK-Cu

A copper peptide researched for skin elasticity, collagen support, and wound healing — a common topic when skin changes show up during perimenopause.

Cycle: Often used on an ongoing basis rather than a strict cycle, sometimes following a 5-days-on/2-days-off pattern.

Epitalon

Studied in longevity research circles for its potential role in sleep regulation and cellular aging pathways.

Cycle: Classic protocols describe short 10–20 day courses, repeated once or twice a year rather than continuous use.

CJC-1295 / Ipamorelin

A commonly studied combination researched for supporting natural growth hormone release — often discussed in the context of sleep quality, recovery, and body composition during midlife.

Cycle: Often cycled for 8–12 weeks, dosed 5 days on / 2 days off, with a break before restarting.

Tesamorelin

Researched specifically around visceral fat and metabolic markers, sometimes discussed by women noticing abdominal weight changes during perimenopause.

Cycle: Typically dosed nightly and used continuously rather than cycled, often over a 12–16 week stretch before reassessment.

Semax

Studied for cognitive support and focus — frequently mentioned by women describing brain fog.

Cycle: Often used in shorter bursts of 10–14 days due to tolerance concerns, dosed intranasally multiple times a day during that window.

Selank

Researched for calming, anti-anxiety effects — often discussed alongside the emotional shifts of perimenopause.

Cycle: Similar to Semax — short 10–14 day courses, dosed intranasally multiple times daily, with a break before resuming.

MOTS-c

Studied for its role in mitochondrial function and metabolic regulation — often discussed in the context of fatigue and low energy.

Cycle: Community reports often describe 4–8 week cycles, dosed a few times a week rather than daily.

SS-31

Researched for mitochondrial protection, sometimes mentioned in conversations about chronic fatigue and recovery.

Cycle: Still mostly confined to research and clinical settings — there isn't an established self-directed cycling pattern yet.

Glutathione

The body's primary antioxidant, researched for cellular detox support, oxidative stress, and skin clarity — often discussed alongside fatigue and "feeling run down" during hormonal shifts.

Cycle: Often used more like an ongoing supplement than a time-limited cycle — commonly a few times a week.

NAD+

The coenzyme behind nearly every cell's energy production, researched for cellular energy, cognitive clarity, and longevity support — often discussed alongside fatigue and brain fog.

Cycle: 4–6 weeks (IM), then 1–2x/week for maintenance.

PT-141

Studied specifically for its effects on sexual desire and arousal — directly relevant to the libido changes many women notice during perimenopause.

Cycle: Used as-needed rather than cycled — typically dosed shortly before activity rather than on a recurring schedule.

Semaglutide

A GLP-1 receptor agonist researched for appetite regulation, blood sugar control, and weight loss.

Cycle: Used continuously rather than cycled, typically weekly, with a gradual dose increase over several weeks under medical supervision to manage side effects.

Tirzepatide

A dual GLP-1/GIP receptor agonist — a different mechanism than semaglutide, researched for stronger effects on appetite and blood sugar.

Cycle: Same continuous, weekly pattern as semaglutide, with a similar gradual titration schedule under medical supervision.

Retatrutide

A triple agonist acting on GLP-1, GIP, and glucagon receptors — a different mechanism than semaglutide or tirzepatide, which is why it's listed separately here. Newer to research, with less long-term data available.

Cycle: Same continuous, weekly, titrated pattern as the others, under medical supervision.

5-Amino-1MQ

Technically not a peptide but commonly discussed alongside them — a small molecule that inhibits an enzyme (NNMT) involved in metabolism, researched for fat loss and NAD+ preservation.

Cycle: Typically taken daily, often over 8–12+ week stretches given its cumulative metabolic effect.